Key points are not available for this paper at this time.
New D-A-type catalysts based on Cu (II) complexes (C1 and C2) including dipyrrin ligands with phenothiazine/carbazole as the meso-substituent have been described. The complexes have been thoroughly characterized by various methods (1H, 13C, ESI-MS, EPR, and UV-vis studies), and structures of both C1 and C2 unequivocally determined by X-ray single crystal analyses. The catalysts C1 and C2 are stable at room temperature and exhibit Faradaic efficiency values of ∼56% (C1) and ∼46% (C2) toward homogeneous reduction of CO2 to CO. The release of CO has been validated by gas chromatographic (GC) studies. Electron-rich phenothiazine and carbazole included in the catalysts facilitate proton transfer, enabling rapid and selective formation of CO over H2 with FEH2 values of ∼22% for C1 and ∼7% for C2 and turnover numbers (TON) of ∼46 for C1 and ∼21 for C2. Furthermore, the formation of formate ions has been affirmed by ion chromatography (C1, ∼16%; C2, ∼18%). Detailed electrochemical studies and product analyses suggested that C1 displays superior catalytic activity relative to C2 which has been further supported by theoretical studies.
Ali et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: